AZ, Daiichi’s Enhertu posts trial win in numerous cancer types. Is a tumor-agnostic approval next? aliu Mon, 03/06/2023 – 11:07 More: AZ, Daiichi's Enhertu posts trial win in numerous cancer types. Is a tumor-agnostic approval next? Source: fierce
read moreModerna picks Oxfordshire for future UK manufacturing and R&D site fkansteiner Mon, 03/06/2023 – 10:02 More: Moderna picks Oxfordshire for future UK manufacturing and R&D site Source: fierce
read moreFDA widens Lilly’s Verzenio breast cancer reach, removes test and menopausal status demands aliu Mon, 03/06/2023 – 09:12 More: FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands Source: fierce
read moreACC23: J&J’s combo pill of Opsumit plus tadalafil improves blood flow in PAH patients kdunleavy Mon, 03/06/2023 – 08:29 More: ACC23: J&J's combo pill of Opsumit plus tadalafil improves blood flow in PAH patients Source: fierce
read moreThe therapy becomes the first pegylated enzyme for the treatment of adult patients with Fabry disease More: Protalix and Chiesi gain positive opinion for pegunigalsidase alfa Source: News
read moreVaccines developed at the facility will cover a wide range of respiratory diseases More: Moderna opts for Oxfordshire in quest for innovation Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals